title: Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Electronic address: donald.banerji@novartis.com.
authors.forename: Donald
authors.initials: D
authors.lastname: Banerji
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Francesco
authors.initials: F
authors.lastname: Patalano
mesh_terms: D001592:Benzyl Alcohols / Q000008:administration & dosage*; D002722:Chlorobenzenes / Q000008:administration & dosage*; D005260:Female; D000068297:Fluticasone-Salmeterol Drug Combination / Q000008:administration & dosage*; D005541:Forced Expiratory Volume / Q000187:drug effects*; D006801:Humans; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*
chemical_list: D001592:Benzyl Alcohols; D002722:Chlorobenzenes; D000068297:Fluticasone-Salmeterol Drug Combination
keywords: Dual bronchodilators; Exacerbations; LABA/ICS; LABA/LAMA; Lung function